Katherine S Panageas
Overview
Explore the profile of Katherine S Panageas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
12149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lochrin S, Kalvin H, Smithy J, Chen M, Momtaz P, Shoushtari A, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39883427
No abstract available.
2.
Mazzella-Ebstein A, Daly R, Huang J, Bernal C, Wilhelm C, Panageas K, et al.
JMIR Hum Factors
. 2025 Jan;
12:e60585.
PMID: 39865555
Background: Remote patient monitoring (RPM) aims to improve patient access to care and communication with clinical providers. Overall, understanding the usability of RPM applications and their influence on clinical care...
3.
Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features
Reiner A, Alici Y, Correa D, Bossert D, Sigler A, Fournier D, et al.
Blood Adv
. 2024 Dec;
9(6):1376-1386.
PMID: 39626273
Anxiety and depression are common in many cancers but, to our knowledge, have not been systematically studied in patients with histiocytic neoplasms (HNs). We sought to estimate rates of anxiety...
4.
Doshi S, Charvadeh Y, Seier K, Bange E, Daly B, Lipitz-Snyderman A, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2445363.
PMID: 39546309
Importance: The COVID-19 pandemic catalyzed rapid adoption of telemedicine visits for cancer care delivery. However, patients' experiences with telemedicine remain poorly understood. Objective: To understand patients' satisfaction with telemedicine visits...
5.
Peng X, Smithy J, Yosofvand M, Kostrzewa C, Bleile M, Ehrich F, et al.
bioRxiv
. 2024 Oct;
PMID: 39416145
Recent progress in multiplexed tissue imaging is advancing the study of tumor microenvironments to enhance our understanding of treatment response and disease progression. Cellular neighborhood analysis is a popular computational...
6.
Jolissaint J, Lobaugh S, Goldman D, McIntyre S, Vos E, Panageas K, et al.
Ann Surg
. 2024 Oct;
PMID: 39355926
Objective: To determine if cancer patients experience variability in incidence or management of emergency general surgery (EGS) conditions compared to non-cancer patients. Background: The true frequency, and natural history of...
7.
Grommes C, Nandakumar S, Schaff L, Gavrilovic I, Kaley T, Nolan C, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4005-4015.
PMID: 38995739
Purpose: Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary...
8.
Bange E, Daly R, Lipitz-Snyderman A, Kuperman G, Polubriaginof F, Liebertz C, et al.
J Natl Cancer Inst Monogr
. 2024 Jun;
2024(64):76-82.
PMID: 38924792
Modern cancer care is costly and logistically burdensome for patients and their families despite an expansion of technology and medical advances that create the opportunity for novel approaches to care....
9.
Schaff L, Carlow D, Schofield R, Wongchai V, Madzsar J, Hyde A, et al.
JCO Oncol Pract
. 2024 Jun;
20(10):1384-1390.
PMID: 38917404
Purpose: High-dose methotrexate (HD-MTX) is the backbone of curative therapy for CNS lymphoma. Because of toxicity, MTX is administered in the inpatient setting along with hyperhydration and monitoring until MTX...
10.
Smithy J, Kalvin H, Ehrich F, Shah R, Adamow M, Raber V, et al.
Clin Cancer Res
. 2024 May;
30(16):3407-3415.
PMID: 38767650
Purpose: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker...